stockrowAMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
Follow AMRX
Alert me
AMNEAL PHARMACEUTICALS, INC. (AMRX) Shares outstanding
AMNEAL PHARMACEUTICALS, INC.'s shares outstanding at the end of fiscal 2025 was $324.8M, up 5.12% from $309.0M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $335.7M. Over the past ten years it has ranged from $71.0M (fiscal 2016) to $324.8M (fiscal 2025) — the current reading is the highest in ten years. AMNEAL PHARMACEUTICALS, INC. ranks 11th of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $324.8M | 5.12% |
| FY2024 | $309.0M | 75.42% |
| FY2023 | $176.1M | 16.69% |
| FY2022 | $150.9M | (0.58%) |
| FY2021 | $151.8M | 1.95% |
| FY2020 | $148.9M | 12.72% |
| FY2019 | $132.1M | 3.81% |
| FY2018 | $127.3M | 71.96% |
| FY2017 | $74.0M | 4.23% |
| FY2016 | $71.0M | (1.43%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $335.7M | 2.33% |
| Jun 2026 | $328.1M | (0.25%) |
| Mar 2026 | $328.9M | 1.27% |
| Dec 2025 | $324.8M | 0.02% |
| 38 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RDY Dr. Reddy's Laboratories Ltd compare | $833.3M |
| ELAN Elanco Animal Health Incorporated compare | $505.9M |
| AMRX AMNEAL PHARMACEUTICALS, INC. | $335.7M |
| HIMS Hims & Hers Health, Inc. compare | $231.7M |
| ALKS Alkermes plc compare | $176.4M |
| SUPN Indivior Pharmaceuticals Inc. compare | $122.0M |
| LQDA Liquidia Corporation compare | $101.4M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $84.9M |
| LNTH Lantheus Holdings, Inc. compare | $68.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on AMRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement